Taken together, our data suggest that BCR-ABL may impair anti-tumor immunity against CML cells by disrupting cDC development and promoting myeloid cell-mediated immune suppression. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.